North America Esophageal Cancer Market Size, Share & Trends Analysis Report By Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma, Others (e.g., small cell carcinoma)), By Diagnosis (Endoscopy, Biopsy, Barium Swallow (Esophagram), Imaging (CT, PET, MRI)), By Country (U.S., Canada) and Forecast, 2026-2034

North America Esophageal Cancer Market Trends

Biomarker-Directed Immunotherapy Reshapes Treatment Pathways

Biomarker testing and checkpoint inhibition are increasingly integrated into treatment selection. The U.S. is expected to record approximately 22,530 new cases and 16,290 deaths in 2026, while Canada expects approximately 2,800 diagnoses and 2,500 deaths. In February 2026, the FDA expanded the PD-L1 IHC 22C3 pharmDx indication to identify patients with esophageal or GEJ carcinoma for pembrolizumab, reinforcing the shift toward biomarker-directed therapy.

Treatment innovation is also broadening administration options and patient selection. The FDA approved subcutaneous nivolumab/hyaluronidase in December 2024 across eligible nivolumab indications, including esophageal carcinoma and esophageal adenocarcinoma. Separately, KEYNOTE-590 enrolled 749 patients, with pembrolizumab plus chemotherapy producing median overall survival of 12.4 months versus 9.8 months for chemotherapy control and median progression-free survival of 6.3 versus 5.8 months.

North America Esophageal Cancer Market Drivers

Expanding Immunotherapy and Precision-Oncology Utilization

High disease mortality and expanding systemic-treatment options support therapy utilization. Of the estimated 22,530 U.S. diagnoses in 2026, 17,580 are in men and 4,950 in women, alongside 16,290 expected deaths. KEYNOTE-590 demonstrated a hazard ratio of 0.73 for overall survival and 0.65 for progression-free survival with pembrolizumab plus chemotherapy, strengthening clinical adoption of immune checkpoint combinations in advanced disease.

North America Esophageal Cancer Market Restraints

High Mortality and Complex Multimodal Treatment Pathways

Disease severity, late diagnosis, toxicity, and multidisciplinary care requirements constrain treatment outcomes. Canada expects approximately 2,500 deaths from 2,800 diagnosed cases in 2026, while U.S. estimates indicate 16,290 deaths from 22,530 cases. KEYNOTE-590 also reported common adverse reactions in at least 20% of combination-treated patients, illustrating the clinical burden associated with systemic regimens.

North America Esophageal Cancer Market Opportunities

Biomarker Testing Creates New Precision-Treatment Pathways

Companion diagnostics offer substantial opportunities as PD-L1, HER2 and emerging molecular markers increasingly determine treatment selection. In July 2026, FDA expanded PD-L1 IHC 28-8 pharmDx labeling for identifying ESCC and esophageal adenocarcinoma patients for nivolumab or subcutaneous nivolumab/hyaluronidase. Earlier KEYNOTE-590 evidence from 749 patients supported pembrolizumab combinations, with median overall survival improving by 2.6 months versus control.

Challanges in North America Esophageal Cancer Market

Clinical Heterogeneity Complicates Treatment Standardization

Differences between adenocarcinoma and squamous histology, biomarker status, disease stage and treatment eligibility create fragmented clinical pathways. U.S. disease incidence remains strongly male-skewed, with 17,580 male cases versus 4,950 female cases estimated for 2026. In Canada, approximately 2,100 men and 680 women are expected to be diagnosed, emphasizing demographic and clinical heterogeneity across a combined addressable population exceeding 25,000 annual cases.

North America Esophageal Cancer Market Segmentation

The industry is segmented by cancer type, diagnosis, treatment, stage, route of administration, end user, and distribution channel. Based on supplied cancer-type values, adenocarcinoma dominates with 45.21% of the 2026 total, followed by squamous cell carcinoma at 39.28% and others at 15.51%.

By Cancer Type. Adenocarcinoma rises from USD 2,879.37 million in 2026 to USD 3,656.01 million in 2034 at a 3.03% CAGR, making it the largest and fastest-expanding supplied cancer-type category. Squamous cell carcinoma advances at 2.92%, while other cancers register 2.72%.

The supplied cancer-type total increases from USD 6,368.86 million in 2026 to USD 8,029.81 million in 2034 at 2.89%, with adenocarcinoma maintaining leadership throughout the forecast period.

By Diagnosis. The market includes endoscopy, biopsy, barium swallow, CT/PET/MRI imaging, esophageal manometry, and blood tests. These modalities support detection, histological confirmation, staging and treatment planning across Stage 0–IV disease.

Endoscopy and biopsy remain central to tissue-based diagnosis, while CT, PET and MRI support staging and metastatic assessment. No segment-specific monetary values or CAGRs were supplied for diagnosis categories.

By Treatment. Therapy segmentation comprises chemotherapy, radiation, targeted therapy, immunotherapy, surgery, endoscopic treatment and palliative care; drug classes include PD-1/PD-L1, HER2 and VEGF inhibitors, cytotoxic agents, TKIs, antimetabolites and others.

Systemic treatment is increasingly biomarker-directed, particularly for advanced disease. No supplied treatment-level values or CAGRs permit numerical ranking without introducing unsupported estimates.

By Stage, Route, End User and Distribution Channel. Stage 0–IV categories span localized through metastatic disease; administration includes oral, intravenous and other routes. Hospitals, specialty cancer centers, research institutes, ASCs and homecare settings constitute end users, while hospital, retail and online pharmacies form distribution channels.

Hospital-based and specialty oncology infrastructure remains essential for intravenous systemic therapy, radiation and surgery. Segment-level values and CAGRs were not provided for these categories and therefore are not numerically extrapolated.

North America Esophageal Cancer Market Counties Outlook

U.S.

The U.S. contributes approximately 79.75% of the supplied 2026 regional value, reaching USD 5,082.67 million from USD 4,929.84 million in 2025. It is forecast to reach USD 6,488.75 million by 2034 at 3.10% CAGR. The country's scale reflects substantial oncology infrastructure and an estimated 22,530 new esophageal cancer diagnoses in 2026.

Canada

Canada represents approximately 20.25% of the supplied 2026 regional total, increasing from USD 1,257.21 million in 2025 to USD 1,290.90 million in 2026 and USD 1,595.07 million by 2034, at a 2.68% CAGR. Approximately 2,800 Canadians are expected to receive an esophageal cancer diagnosis in 2026, including 2,100 men and 680 women.

Top players in North America Esophageal Cancer Market

• Merck & Co., Inc.
• Bristol Myers Squibb
• BeiGene/BeOne Medicines
• AstraZeneca
• Roche
• Eli Lilly and Company
• Pfizer Inc.
• Amgen Inc.
• Novartis AG
• Astellas Pharma Inc.
• Johnson & Johnson
• Sanofi
• Daiichi Sankyo
• Gilead Sciences
• Regeneron Pharmaceuticals

Top Two Companies

• Merck & Co., Inc.

Exact company revenue percentages within the defined market are not supplied and should not be fabricated. Merck holds a prominent therapeutic position through pembrolizumab. KEYNOTE-590 randomized749 patients, and pembrolizumab plus chemotherapy achieved median overall survival of12.4 months, compared with9.8 monthsfor chemotherapy control, with an OS hazard ratio of0.73. The FDA's February 2026 PD-L1 IHC 22C3 companion-diagnostic labeling expansion further reinforces biomarker-supported pembrolizumab positioning in esophageal/GEJ carcinoma.

• Bristol Myers Squibb

Exact company percentage contribution is not available from the mandatory dataset. Bristol Myers Squibb remains strongly positioned through nivolumab, including its subcutaneous formulation approved in December 2024. Historical ESCC evidence showed median overall survival of10.9 months versus 8.4 monthswith taxane chemotherapy, corresponding to an OS hazard ratio of0.77. In July 2026, FDA also expanded PD-L1 IHC 28-8 pharmDx labeling for selection of eligible esophageal cancer patients receiving nivolumab or Opdivo Qvantig.

Recent Developments in North America Esophageal Cancer Market

• 2026:FDA expanded PD-L1 IHC 28-8 pharmDx indications in July to aid selection of ESCC and esophageal adenocarcinoma patients for nivolumab or nivolumab/hyaluronidase.
• 2026:FDA expanded PD-L1 IHC 22C3 pharmDx labeling in February for identifying esophageal or GEJ carcinoma patients for pembrolizumab treatment.
• 2025:Tislelizumab gained a U.S. first-line ESCC indication with platinum-containing chemotherapy for tumors expressing PD-L1 ≥1; its orphan exclusivity for this indication extends to2032.
• 2025:FDA granted traditional approval to pembrolizumab plus trastuzumab and chemotherapy for eligible HER2-positive gastric/GEJ adenocarcinoma following evidence from a698-patienttrial.

Research Methodology

The study applies a combined top-down and bottom-up framework using 2025 as the base year, 2026 as the current year, 2022–2024 as historical years, and 2026–2034 as the forecast period. Mandatory supplied monetary figures were retained without alteration; percentage contributions were calculated directly from those values. Secondary validation incorporated authoritative U.S. and Canadian cancer statistics and FDA regulatory records. Forecast interpretation evaluates cancer type, diagnosis, therapy, stage, administration route, end user and distribution channel while avoiding unsupported numerical extrapolation where segment-specific values were not supplied.